RAPT Therapeutics, Inc. (NASDAQ:RAPT) to Post Q2 2022 Earnings of ($0.75) Per Share, SVB Leerink Forecasts

RAPT Therapeutics, Inc. (NASDAQ:RAPTGet Rating) – Investment analysts at SVB Leerink lifted their Q2 2022 earnings per share estimates for shares of RAPT Therapeutics in a research report issued on Wednesday, May 11th. SVB Leerink analyst T. Smith now expects that the company will earn ($0.75) per share for the quarter, up from their previous estimate of ($0.78). SVB Leerink also issued estimates for RAPT Therapeutics’ Q3 2022 earnings at ($0.81) EPS, Q4 2022 earnings at ($0.90) EPS, FY2022 earnings at ($3.16) EPS, FY2023 earnings at ($4.29) EPS, FY2024 earnings at ($3.89) EPS, FY2025 earnings at ($0.85) EPS and FY2026 earnings at $0.02 EPS.

RAPT Therapeutics (NASDAQ:RAPTGet Rating) last posted its quarterly earnings data on Wednesday, May 11th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.01). RAPT Therapeutics had a negative return on equity of 36.23% and a negative net margin of 2,263.55%.

A number of other equities analysts also recently commented on RAPT. Zacks Investment Research downgraded shares of RAPT Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 20th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of RAPT Therapeutics in a report on Friday, April 1st. Wells Fargo & Company reduced their price target on shares of RAPT Therapeutics from $65.00 to $55.00 and set an “overweight” rating on the stock in a research report on Friday, March 11th. Roth Capital reiterated a “buy” rating on shares of RAPT Therapeutics in a research report on Wednesday, March 16th. Finally, HC Wainwright restated a “buy” rating and issued a $56.00 target price on shares of RAPT Therapeutics in a research report on Monday, March 14th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, RAPT Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $52.25.

Shares of RAPT stock opened at $14.41 on Monday. The firm has a market capitalization of $426.15 million, a price-to-earnings ratio of -5.63 and a beta of 0.99. RAPT Therapeutics has a 12-month low of $9.85 and a 12-month high of $43.26. The firm has a fifty day moving average of $19.58 and a 200-day moving average of $25.82.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Perceptive Advisors LLC increased its position in RAPT Therapeutics by 19.6% in the third quarter. Perceptive Advisors LLC now owns 2,907,565 shares of the company’s stock worth $90,280,000 after purchasing an additional 476,905 shares during the last quarter. Morgan Stanley lifted its stake in RAPT Therapeutics by 120.3% in the third quarter. Morgan Stanley now owns 763,744 shares of the company’s stock worth $23,714,000 after acquiring an additional 417,015 shares during the period. Dupont Capital Management Corp purchased a new stake in RAPT Therapeutics in the fourth quarter worth about $209,000. Franklin Resources Inc. purchased a new stake in RAPT Therapeutics in the third quarter worth about $394,000. Finally, Squarepoint Ops LLC lifted its stake in RAPT Therapeutics by 109.5% in the third quarter. Squarepoint Ops LLC now owns 25,359 shares of the company’s stock worth $787,000 after acquiring an additional 13,257 shares during the period. Institutional investors own 95.22% of the company’s stock.

In other RAPT Therapeutics news, insider Dirk G. Brockstedt sold 2,648 shares of the firm’s stock in a transaction dated Friday, March 11th. The shares were sold at an average price of $23.91, for a total transaction of $63,313.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Rodney Kb Young acquired 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 10th. The stock was acquired at an average cost of $10.53 per share, for a total transaction of $52,650.00. Following the acquisition, the chief financial officer now owns 10,084 shares of the company’s stock, valued at approximately $106,184.52. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 1,259,500 shares of company stock valued at $13,440,730 and have sold 12,015 shares valued at $260,413. Corporate insiders own 5.00% of the company’s stock.

RAPT Therapeutics Company Profile (Get Rating)

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Recommended Stories

Earnings History and Estimates for RAPT Therapeutics (NASDAQ:RAPT)

Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.